CompletedPhase 2NCT02419287

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Studying ALK-negative anaplastic large cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Milano Bicocca
Principal Investigator
Carlo Gambacorti Passerini, MD, M.D
University of Milano Bicocca
Intervention
crizotinib(drug)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20152022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02419287 on ClinicalTrials.gov

Other trials for ALK-negative anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for ALK-negative anaplastic large cell lymphoma

← Back to all trials